Chiroscience signs deal for asthma drug
Saturday 28 June 1997
The US group, regarded as number three in the treatment of respiratory diseases, will underwrite the research and development of Chiroscience's class of anti-inflammatory treatments known as PDE IV inhibitors, including what is being claimed as the leading treatment for asthma, codenamed D4418. In exchange, Schering will be given exclusive world-wide rights to any drugs which result from the research.
John Padfield, Chiroscience chief executive, said asthma was a growing problem, affecting some 14 per cent of the Western World's population. "To be working on our PDE IV inhibitors with a company of the calibre of Schering-Plough is exciting and acknowledges the success we have achieved to date with D4418 and other research compounds," he said.
Chiroscience estimates the Western market for asthma drugs is worth around $4bn, but claims that only half of all sufferers are treated due to difficulties in using treatments. Children, for instance, have problems using inhalers to take drugs such as Glaxo's Becotide, one of the leading treatments for asthma. Chiroscience's product will be in pill form. However, it is not expected to reach the market before 2003, even if it clears clinical trials currently under way in phase I.
Last year, Celltech, another biotech group, and Merck of the US abandoned development of a rival PDE IV-based product, codenamed CDP840. Chiroscience now reckons it has the lead in this class of drug, which it claims is the only one which attacks all four main components of asthma - wheezing at the beginning and after an attack and the associated inflammation and phlegm brought up from the stomach.
Other uses for the treatment being researched include chronic bronchitis, rheumatoid arthritis and the skin conditions atopic eczema and psoriasis.
The group will receive an initial licence fee, milestone payments and research and development finance under the Schering deal, with any royalty payments coming in on top of the initial $38m maximum.
Separately, Shire Pharmaceuticals, another biotech group, announced it had secured certain exclusive marketing rights to distribute Urispas, a urinary treatment, from Recordati of Italy.
- 1 Tamir Rice: 12-year-old boy playing with fake gun dies after being shot by Ohio police
- 2 To help fuel their propaganda machine against the poor, our government has now decided to redefine the word 'welfare'
- 3 Bill Cosby: Isn’t it obvious why his accusers have stayed silent up until now?
- 4 Halle Berry takes ex-boyfriend Gabriel Aubry to court for allegedly trying to make daughter look less African-American
- 5 Isis propaganda image showing 'abuse of Muslim woman by soldiers' is actually taken from Hungarian porn film
Tamir Rice: 12-year-old boy playing with fake gun dies after being shot by Ohio police
Ferguson decision: Tea Party website mocks Michael Brown's family over T-shirt typo
Michael Brown shooting: Ten things we know – or know better – now the Ferguson grand jury's work is over
Isis propaganda image showing 'abuse of Muslim woman by soldiers' is actually taken from Hungarian porn film
Derren Brown on the disappointment of coming out: 'It’s not that people react badly to it – they really don't care'
Rochester by-election: Ukip gains second MP as Tory defector Mark Reckless holds seat
'Beast of Bolsover' Dennis Skinner takes Ukip MP Mark Reckless to task moments after he is sworn in
Rochester by-election: Labour MP Emily Thornberry resigns after posting white van and England flags tweet
The young are the new poor: Sharp increase in number of under-25s living in poverty, while over-65s are better off than ever
Revealed: How the world gets rich – from privatising British public services
Exclusive: UK approved £7m Israeli arms sales in six months before Gaza conflict
iJobs Money & Business
£Attractive: Citifocus Ltd: High calibre individual with significant product d...
£Negotiable: Citifocus Ltd: Leading global bank seeks experienced credit analy...
£Attractive Package: Citifocus Ltd: High calibre individual with a high degree...
£Attractive: Citifocus Ltd: High calibre individual with superior academics an...